Loading
Latest filing published 09 Dec 2022 for SAB Biotherapeutics, Inc., €48k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
David Charles Link is a declared insider of SAB Biotherapeutics, Inc. (board member), with filings sourced from SEC (Form 4). We count 3 filings; the first trade dates from 22 October 2021 and the latest from 7 December 2022.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 9 December 2022, reports a share grant of €48k in SAB Biotherapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations